← All trials
NCT05998759
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Aug 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 296
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityReponsible party - principal investigator
- Peking UniversityStudy chair
- Changhai HospitalCollaborator
- Changhai HospitalOverall official - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
- China Medical UniversityCollaborator
- China Medical UniversityOverall official - principal investigator
- Shantou UniversityCollaborator
- Shantou UniversityOverall official - principal investigator
- China Academy of Chinese Medical SciencesCollaborator
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- Peking UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- Peking UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- Xinjiang Medical UniversityCollaborator
- Xinjiang Medical UniversityOverall official - principal investigator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
- Central South UniversityCollaborator
- Central South UniversityOverall official - principal investigator
- Shandong Provincial HospitalCollaborator
- Shandong Provincial HospitalOverall official - principal investigator
- Shanxi Bethune HospitalCollaborator
- Shanxi Bethune HospitalOverall official - principal investigator
- Inner Mongolia Medical UniversityCollaborator
- Inner Mongolia Medical UniversityOverall official - principal investigator
- Zhengzhou UniversityCollaborator
- Zhengzhou UniversityOverall official - principal investigator
- The First People's Hospital of Yunan ProvinceCollaborator
- The First People's Hospital of Yunan ProvinceOverall official - principal investigator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityOverall official - principal investigator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityOverall official - principal investigator
- Sichuan UniversityCollaborator
- Sichuan UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Central South UniversityCollaborator
- Central South UniversityOverall official - principal investigator
- China Medical UniversityOfficial
- Inner Mongolia Medical UniversityOfficial
- Tianjin Medical UniversityOfficial
- Tianjin Medical UniversityOfficial
- China Academy of Chinese Medical SciencesOfficial
- Xinjiang Medical UniversityOfficial
- The First People's Hospital of Yunan ProvinceOfficial
- Sichuan UniversityOfficial
- Shanxi Bethune HospitalOfficial
- Anhui Medical UniversityCollaborator
- Huazhong University of Science and TechnologyOfficial
- Peking UniversityOfficial
- Peking UniversityOfficial
- Peking UniversityOfficial
- Shandong Provincial HospitalOfficial
- Zhengzhou UniversityOfficial
- Changhai HospitalOfficial
- Shantou UniversityOfficial
- University of Science and Technology of ChinaCollaborator
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Central South UniversityOfficial
- Peking UniversitySponsor investigator
- Sun Yat-Sen UniversityOfficial
- University of Science and Technology of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.